Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 66,900 shares, the days-to-cover ratio is currently 0.8 days.
Analysts Set New Price Targets
A number of research firms recently commented on MNPR. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a "buy" rating in a research report on Wednesday, January 22nd. Piper Sandler started coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an "overweight" rating and a $72.00 price target on the stock.
View Our Latest Stock Analysis on MNPR
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. acquired a new position in Monopar Therapeutics in the fourth quarter valued at $45,000. Geode Capital Management LLC raised its holdings in shares of Monopar Therapeutics by 174.4% in the 4th quarter. Geode Capital Management LLC now owns 38,596 shares of the company's stock worth $849,000 after purchasing an additional 24,530 shares during the period. ADAR1 Capital Management LLC acquired a new position in shares of Monopar Therapeutics in the 4th quarter valued at about $2,861,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $13,182,000. Finally, RA Capital Management L.P. purchased a new stake in shares of Monopar Therapeutics during the 4th quarter worth about $11,247,000. Institutional investors and hedge funds own 1.83% of the company's stock.
Monopar Therapeutics Stock Up 15.1 %
Shares of MNPR stock traded up $4.48 during mid-day trading on Monday, hitting $34.23. 22,846 shares of the company's stock were exchanged, compared to its average volume of 360,360. The stock has a market cap of $208.87 million, a price-to-earnings ratio of -17.38 and a beta of 1.18. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The stock has a 50-day simple moving average of $35.77 and a two-hundred day simple moving average of $21.54.
About Monopar Therapeutics
(
Get Free Report)
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Featured Stories
Before you consider Monopar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monopar Therapeutics wasn't on the list.
While Monopar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.